Does Ascorbic Acid Reduce Sympathoexcitation in CHF?

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00550121

Enrollment

Unknown

Registered

2007-10-26

Start date

2007-08-31

Completion date

2008-04-30

Last updated

2008-10-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Failure

Brief summary

In CHF central sympathetic activity is increased. ROS formation seems to play a role in this process. This study analyzes the effect of vitamin C as an antioxidant on central sympathetic activity in CHF

Interventions

DRUGvitamin C

DRUGplacebo

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

20 Years to 80 Years

Inclusion criteria

* Heart failure of at least New York Heart Association (NYHA) class II * Left ventricular ejection fraction (LVEF) \<= 40% * Age 20-80 years

Exclusion criteria

* Necessity of short-term PCI, CABG or heart transplantation, * Chronic disease of the autonomic nervous system, * diabetes mellitus, * use of tricyclic antidepressant drugs and/or a-adrenergic receptor antagonists.

Design outcomes

Primary

Measure	Time frame
change in central sympathetic output after vitamin C vs. placebo	—

Countries

Netherlands

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026